

SUNDAY 13 SEPTEMBER			
12.00pm	Registration opens – Plaza Level		
8.30am–10.30am	Symposium: Innovations in program design for sexual and reproductive health (BCEC – Room P1, Plaza Level) <i>Chairs: Sevgi Aral & James Blanchard</i>		
8.30am–9.00am	Enhancing program efficiency of voluntary medical male circumcision for HIV prevention: A novel modelling approach. <i>Suzanne Awad</i>		
9.00am–9.30am	Achieving maximal health impact with available resources: balancing the science, economics, and politics of HIV. <i>Cliff Kerr</i>		
9.30am–10.00am	Optimizing HIV management strategies through an integrated quantitative/mathematical framework. <i>Babak Pourbohloul</i>		
10.00am–10.30am	MSM Program in Ghana – successful new approaches to improve coverage. <i>Nana Clement</i>		
10.30am–11.00am	Morning Tea in Foyer P1		
11.00am–12.30pm	Symposium: Innovations in program design for sexual and reproductive health (Room P1, Plaza Level) <i>Chairs: Sevgi Aral & James Blanchard</i>		
11.00am–11.30am	Adolescent linkage to STD/HIV Prevention: The role of partnerships, targeting, and tailoring. <i>Patricia Dittus</i>		
11.30am–12.00pm	Assessing programme impact through multiple non-experimental methods: The case of chlamydia screening in England and other stories. <i>Anne Johnson</i>		
12.00pm–12.30pm	Improving quality and efficiency within the English National Chlamydia Screening Programme: using a program science approach to develop a quality care pathway. <i>John Saunders</i>		
12.30pm–1.30pm	Lunch in Foyer P1 Full congress registration opens – Registration Desk, Foyer Level		
1.30pm–3.00pm	Symposium: Innovations in program design for sexual and reproductive health – Epidemiology Room: P1, Plaza Level <i>Chairs: Sevgi Aral & James Blanchard</i>	1.30pm – 3.00pm	Symposium S01 A strategy for HIV/STI prevention in low and middle income countries (Bill and Melinda Gates Foundation) Room: M3 Mezzanine Chairs: Gina Dallabetta & Saul Johnson
1.30pm–2.00pm	Spatial epidemiology of HIV Infection in sub-Saharan Africa: A methodology for identifying populations at high risk of HIV infection in sub-Saharan Africa. <i>Diego Cuadros</i>	1.30pm–1.45pm	S01.1 HIV and STI Prevention: What is an Intervention? <i>James Hargreaves</i>
		1.45pm–2.00pm	S01.2 Systematic reviews of the efficacy and effectiveness of biological, behavioral and structural HIV prevention interventions. <i>Shari Krishnaratne</i>
			Symposium S02 Education about Sex and Relationships: New directions in school and beyond (ASHA) Rooms: M1&2 Mezzanine Chairs: Jayne Lucke & Sarah Hawkes
			S02.1 Sex and relationships education in schools: A key component of sexual health promotion. <i>Peter Aggleton</i>
			S02.2 Religious and faith-based beliefs: A help or a hindrance in sexual health education? <i>Mary Lou Rasmussen</i>

SUNDAY 13 SEPTEMBER

2.00pm–2.30pm	HIV among people who inject drugs in the Middle East and North Africa: State of the epidemic and epidemic potential. <i>Ghina Mumtaz</i>	2.00pm–2.15pm	S01.3 Delivery of HIV/STI prevention interventions: prevention cascades. <i>Geoff Garnett</i>	S02.3 Respecting gender and sexual difference to promote sexual health: making schools safe spaces for all. <i>Kerry Robinson</i>
		2.15pm–2.30pm	S01.4 Modelling the cost effectiveness of HIV prevention interventions. <i>Tim Hallett</i>	S02.4 Engaging boys and men as actors in violence prevention. <i>Bonney Corbin</i>
2.30pm–3.00pm	Venue affiliation networks of newly diagnosed HIV–infected MSM in Baltimore, Maryland. <i>Jacky Jennings</i>	2.30pm–2.45pm	S01.5 The architecture for prevention and the role of targets and indicators. <i>Saul Johnson</i>	S02.5 The politics of pleasure in sexuality education: young people's perspectives. <i>Louisa Allen</i>
		2.45pm–3.00pm	Q&A	Q&A
3.00pm–3.30pm	Afternoon Tea in Foyer P1	3.00pm–3.30pm	Afternoon Tea in M3	Afternoon Tea in M1 & M2
3.30pm–5.00pm	One Day Program Science Symposium Room: P1, Plaza Level	3.30pm–5.00pm	Symposium S03 New global and regional estimates of prevalent and incident STI (WHO) Room: M3 – Mezzanine Level – Chairs: Nicola Low & Nathalie Broutet	
3.30pm–4.00pm	Mapping and estimating the population size of young women engaged in casual, transactional and formal sex work in Mombasa, Kenya and Dnipropetrovsk, Ukraine. <i>Eve Cheuk</i>	3.30pm–3.50pm	S03.1 Global and regional estimates of chlamydia, gonorrhoea, trichomoniasis and syphilis in 2012. <i>Sami Gottlieb</i>	
		3.50pm–4.10pm	S03.2 Global and regional estimates of HSV2, HSV1 and neonatal herpes for 2012. <i>Katherine Turner</i>	
4.00pm–4.30pm	Using hot spots to target STD prevention and treatment. <i>Kyle Bernstein</i>	4.10pm–4.30pm	S03.3 STI estimates within the Institute for Health Metrics and Evaluation Global Burden of Disease process. <i>Nick Kassebaum</i>	
4.30pm–5.00pm	Wrap-up – Program Science: New Horizons. <i>Sevgi Aral</i>	4.30pm–4.50pm	S03.4 Future directions for global STI Estimates. <i>Teodora Wi</i>	
		4.50pm–5.00pm	Q&A	
5.30pm–6.00pm	Official Congress Opening – Great Hall 1 – Entry Door 6 Mezzanine Traditional Welcome Ceremony			
6.00pm–7.00pm	KL - Keynote Lecture Vaccines against STIs: where have we got to? Professor Ian Frazer, CEO and Research Director, Translational Research Institute, QLD, Australia Room: Great Hall 1 – Door 6 – Mezzanine Level and Great Hall 2 – Door 8 – Mezzanine Level Chairs: Basil Donovan & David Lewis			
7.00pm–8.30pm	Welcome Reception and Poster Viewing – Exhibition Hall 1			

MONDAY 14 SEPTEMBER

7.00am	Registration opens – Conference Foyer										
7.30am – 9.00am	Roche Integrated Symposium The Power of Knowing: Pursuing Improved Pathways to Better Patient Solutions Room: M3 – Mezzanine Level Welcome and opening comment. Michael Lewinski, PhD, Director of Clinical Research, Roche Molecular Diagnostics, Pleasanton, CA, USA Defining the medical value of molecular and serologic testing of STIs for patient management. Edward Hook III, MD, University of Alabama, USA Diagnostics for chlamydial and gonococcal infections in China: Current status and future perspectives. Chen Xiang–sheng, PhD, Chinese Center for Disease Control, China Sexually Transmitted Infections: Getting worse or getting better? Basil Donovan, MD, Kirby Institute for Infection and Immunity in Society, Australia Closing and Q & A, Michael Lewinski, PhD – Director of Clinical Research, Roche Molecular Diagnostics, Pleasanton, CA, USA Continental breakfast provided					7.30am – 9.00am	Symposium Y01 Surviving and thriving in STI research: research tools for young investigators (ASTDA/BMJ/CSIRO Publishing/Wiley/Taylor & Francis) Room: M1&2, Mezzanine Level Chairs: Kees Rietmeijer&Hammad Ali				
		7.30am–7.50am	Y01.1 What is the new editor of Sexually Transmitted Diseases going to do with the journal? <i>William Miller</i>								
		7.50am–8.10am	Y01.2 Inside the world of journal publishing. <i>Ginny Barbour</i>								
		8.10am–8.30am	Y01.3 What do funders want to see in a research proposal? <i>Carolyn Deal</i>								
		8.30am–9.00am	Meet the editors: Sexually Transmitted Infections (<i>Jackie Cassell</i>); Sexual Health (<i>Kit Fairley</i>); Culture, Health and Sexuality (<i>Peter Aggleton</i>); Cochrane STI Group (<i>Cindy Farquhar</i>), Sexually Transmitted Diseases (<i>Williams Miller</i>)								
9.15am – 10.45am	PL01 Plenary Session 1 – Great Hall 4 – Door 1 Foyer Chairs: Angelika Stary & William Miller										
9.15am – 9.45am	PL01.1 Gollow Lecture: STI and sustainable development in 2015 and beyond Dr Helen Rees, Executive Director, Wits Reproductive Health & HIV Institute and Professor of Obstetrics and Gynaecology, University of Witwatersrand, Johannesburg, South Africa, and Honorary Professor, London School of Hygiene and Tropical Medicine, London, United Kingdom										
9.45am – 10.15am	PL01.2 STI and the open access revolution in publishing Dr Virginia Barbour, Executive Officer, Australian Open Access Support Group, Brisbane, Australia, Founding co–editor of PLOS Medicine and Chair of the Committee on Publication Ethics										
10.15am – 10.45am	PL01.3 The genomics of Chlamydia trachomatis: A constant surprise Dr Nick Thomson, Faculty and group head, Pathogen Genetics, Wellcome Trust Sanger Institute, Cambridge and Professor of Bacterial Genomics and Evolution, Department of Pathogen Molecular Biology, London School of Hygiene & Tropical Medicine, London, United Kingdom										
10.45am – 11.15am	Morning Tea and Poster Viewing in Exhibition Hall 1										
11.15am – 12.45pm	O01 Spread of antimicrobial resistant gonorrhoea	11.15am – 12.45pm	O02 Point-of–care STI diagnosis	11.15am – 12.45pm	O03 Extragenital STIs	11.15am – 12.45pm	O04 Adolescent Sexual Health	11.15am – 12.45pm	S04 Revealed: Neglected and emerging STIs	11.15am – 12.45pm	S05 STIs in vulnerable and high risk populations in the USA (CDC)
	Room: Great Hall 1 – Door 6 Mezzanine Chairs: Amina Hançali & Magnus Unemo		Room: Great Hall 2 – Door 8 Mezzanine Chairs: Charlotte Gaydos & Tania Crucitti		Room: M3 – Mezzanine Chairs: Richard Hillman & William Geisler		Room: M1&2 – Mezzanine Chairs: Dennis Fortenberry & Deborah Bateson		Room: Great Hall 3 – Door 4 Foyer Level Chairs: David Lewis & Sally Roberts		Room: Great Hall 4 – oor 1 Foyer Level Chairs: Sevgi Aral & Gail Bolan
11.15am – 11.30am	O01.1 Evolution and Spread of Antibiotic Resistant Gonorrhoea. <i>Stephanie Fingerhuth</i>	11.15am – 11.30am	O02.1 Immediate Treatment of Curable Sexually Transmitted and Genital Infections Among Antenatal Women in Papua New Guinea. <i>Steven Badman</i>	11.15am – 11.30am	O03.1 Correlates of repeat anorectal infections among men who have sex with men. <i>Fabian Kong (ISSTDR Scholarship)</i>	11.15am – 11.30am	O04.1 Longitudinal Experiences of Social Support and Sexual Risk in a Sample of Young Black Gay and Bisexual Males. <i>Renata Arrington-Sanders</i>	11.15am – 11.35am	S04.1 <i>Haemophilus ducreyi</i> in “yaws” ulcers in Papua New Guinea. <i>Oriol Mitjà</i>	11.15am – 11.30am	S05.1 Adolescent chlamydia rates adjusted for sexual experience and activity. <i>Patricia Dittus</i>

MONDAY 14 SEPTEMBER											
11.30am–11.45am	O01.2 Azithromycin-resistant <i>Neisseria gonorrhoeae</i> in Men who have Sex with Men (MSM) in Seattle, Washington: 2014–2015. <i>Matthew Golden</i>	11.30am–11.45am	O02.2 Operational Performance of a New Molecular-Based Point-Of-Care Test for Diagnosis of <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> Infection: Concordance with Conventional Laboratory Testing. <i>Louise Causer (ISSTDR Scholarship)</i>	11.30am–11.45am	O03.2 The contribution of <i>Mycoplasma genitalium</i> to the aetiology of sexually acquired proctitis in men who have sex with men. <i>Melanie Bissessor</i>	11.30am–11.45am	O04.2 A Pilot Randomized Controlled Trial of an Interactive Computer-Based Intervention for Sexual Health in Adolescents and Young Adults. <i>Taraneh Shafii</i>	11.35am–11.55am	S04.2 New diagnostics for syphilis and yaws and detection of <i>Haemophilus ducreyi</i> in cutaneous lesions in children. <i>Allan Pillay</i>	11.30am–11.45am	S05.2 Adolescent chlamydia rates adjusted for screening heterogeneity. <i>Lizzi Torrone</i>
11.45am–12.00pm	O01.3 High-Level Azithromycin Resistance In <i>Neisseria gonorrhoeae</i> Clinical Isolates In Nanjing, China, 2013–2014. <i>Xiaohong Su</i>	11.45am–12.00pm	O02.3 Are Rapid Point-of-Care Tests for Syphilis Useful in Outbreak Settings in Remote Australia? – An Experience from the Northern Territory. <i>Jiunn-Yih Su</i>	11.45am–12.00pm	O03.3 The Prevalence of <i>Mycoplasma genitalium</i> and <i>Chlamydia trachomatis</i> at Various Anatomical Sites of Men Who Have Sex with Men in Five Cities of China. <i>Juan Jiang</i>	11.45am–12.00pm	O04.3 Adolescent Care-Seeking Behavior After Notification of Positive Sexually Transmitted Infection Results. <i>Maria Trent</i>			11.45am–12.00pm	S05.3 Calculating risk among men who have sex with men. <i>Kyle Bernstein</i>
12.00pm–12.15pm	O01.4 Recent Rise in Reduced Susceptibility to Ceftriaxone In <i>Neisseria gonorrhoeae</i> Is Not Caused By Strains With A PenA Mosaic Gene. <i>Alje Van Dam</i>	12.00pm–12.15pm	O02.4 Field Evaluation of Standard Diagnostics Duo HIV and Syphilis Test Among Female Sex-Workers in Johannesburg. <i>Vivian Black</i>	12.00pm–12.15pm	O03.4 What explains anorectal chlamydia detection in women: implications for control strategies. <i>Janneke Heijne</i>	12.00pm–12.15pm	O04.4 Pill Dumping in Adolescents Receiving a Boosted Protease Inhibitor Regimen as part of Second-Line Antiretroviral Therapy: Experiences from an Urban HIV Clinic. <i>Tunishe Mudzviti (ISSTDR Scholarship)</i>	11.55am–12.15pm	S04.3 What has Ebola virus to do with sexually transmitted infections? <i>Nicola Low</i>	12.00pm–12.15pm	S05.4 Potential incongruities in relative measures of disparities in sexually transmitted diseases. <i>Harrell Chesson</i>
12.15pm–12.30pm	O01.5 An Australia-wide molecular study of <i>Neisseria gonorrhoeae</i> identifies frequent occurrence of a key cephalosporin resistance mechanism. <i>Ella Trembizki (ISSTDR Scholarship)</i>	12.15pm–12.30pm	O02.5 Evaluation of Five Rapid Point-Of-Care Tests for Syphilis: Two Treponemal only, and Three Dual Treponemal / HIV Assays. <i>Yetunde Fakila</i>	12.15pm–12.30pm	O03.5 Clinician-Taken Extra-Genital Samples for Gonorrhoea and Chlamydia in Women Compared with Self-Taken Samples Analysed Separately and Self-Taken Pooled Samples. <i>Janet Wilson</i>	12.15pm–12.30pm	O04.5 The Influence of Sexual Debut on Selected Vaginal, Rectal and Oral Microbiota and Vaginal Inflammatory Markers in Belgian Adolescent Girls: A Cohort Study. <i>Vicky Jespers</i>	12.15pm–12.35pm	S04.4 Trachoma strains in Indigenous Australian populations are variants of urogenital <i>Chlamydia trachomatis</i> . <i>Phillip Giffard</i>	12.15pm–12.30pm	S05.5 Network formation as a determinant of spatial disparity. <i>Ian Spicknall</i>
12.30pm–12.45pm	O01.6 Exploring the benefits of molecular testing for gonorrhoea antibiotic resistance surveillance in remote settings. <i>Ben Hui</i>	12.30pm–12.45pm	O02.6 A Low-Cost Mobile NAAT Platform for <i>Chlamydia trachomatis</i> . <i>Dong Jin Shin (ISSTDR Scholarship)</i>	12.30pm–12.45pm	O03.6 Timing of Test of Cure for Anogenital <i>Neisseria gonorrhoeae</i> Infections – A Prospective Cohort Study Using Nucleic Acid Amplification Tests. <i>Carolien Wind (ISSTDR Scholarship)</i>	12.30pm–12.45pm	O04.6 High Prevalence of Bacterial Vaginosis among Adolescent Girls Attending Secondary School in Tanzania. <i>Suzanna Francis</i>	12.35pm–12.45pm	Q&A	12.30pm–12.45pm	Q&A

MONDAY 14 SEPTEMBER											
12.45pm–1.45pm Lunch and Poster Viewing in Exhibition Hall 1											
1.45pm–3.15pm	O05 Detecting antimicrobial resistance and treatment failure	1.45pm–3.15pm	O06 STI therapy: New and old	1.45pm–3.15pm	O07 Sexual behaviour and STI in men who have sex with men	1.45pm–3.15pm	O08 Violations of human rights in relation to STI and HIV	1.45pm–3.15pm	S06 STI vaccines: Advancing the global agenda (WHO)	1.45pm–3.15pm	S07 Hooking up with new technology: Influences on young people's sexual health (ASHA)
	Room: Great Hall 1 – Door 6 Mezzanine Chairs: David Whiley & Barbara Van Der Pol		Room: Great Hall 2 – Door 8 – Mezzanine Chairs: Brad Stoner & Jonathan Ross		Room: M3 – Mezzanine Chairs: Helen Ward & Andrew Grulich		Room: M1&2 – Mezzanine Chairs: Peter Aggleton & Chavalit Mangkalaviraj		Room: Great Hall 3 – Door 4 Foyer Chairs: Helen Rees & Carolyn Deal		Room: Great Hall 4 – Door 1 Foyer Chairs: Meredith Temple-Smith & Jennifer Walker
1.45pm–2.00pm	O05.1 Real-time PCR and Melt Curve Analysis Targeting <i>gyrA</i> gene for Prediction of Ciprofloxacin Resistance in Clinical <i>Neisseria gonorrhoeae</i> Isolates. <i>Peera Hemarajata</i>	1.45pm–2.00pm	O06.6 High Prevalence of Chlamydia and Gonorrhoea among Patients with Genital Ulcer Disease in Zimbabwe: Potential Implications for Syndromic Management. <i>More Mungati</i>	1.45pm–2.00pm	O07.1 New and Traditional Notification Tools Improve Partner Notification Outcomes among MSM with Syphilis Infection in Lima, Peru. <i>Jesse Clark</i>	1.45pm–2.00pm	O08.1 How far violation of bodily rights of women is linked to sexual and reproductive morbidities? A study of India and select states & districts. <i>Ankita Siddhanta (ISSTDR Scholarship)</i>	1.45pm–2.05pm	S06.1 The global roadmap for STI vaccine development: Moving forward. <i>Sami Gottlieb</i>	1.45pm–2.00pm	S07.1 New technologies and sexual health promotion. <i>Megan Lim</i>
2.00pm–2.15pm	O05.2 Diagnostic and Clinical Implications of Genotypic Fluoroquinolone Susceptibility Detection for <i>Neisseria gonorrhoeae</i> . <i>Marcus Pond (ISSTDR Scholarship)</i>	2.00pm–2.15pm	O06.2 High in Vitro Susceptibility to the Novel Spiropyrimidinetrione AZD0914 among 873 Contemporary Clinical <i>Neisseria gonorrhoeae</i> Isolates in 21 European Countries During 2012–2014. <i>Magnus Unemo</i>	2.00pm–2.15pm	O07.2 Can Human Papillomavirus (HPV) Biomarkers Help Predict Patterns of Anal High-Grade Squamous Intraepithelial Lesion (HSIL) Detection in Homosexual Men? <i>Fengyi Jin</i>	2.00pm–2.15pm	O08.2 Stigma predicts severity of Major Depressive Disorder in Women Living with HIV in rural India. <i>Not presented</i>	2.05pm–2.25pm	S06.2 Herpes simplex vaccine development: Pipeline and possibilities. <i>Christine Johnston</i>	2.00pm–2.15pm	S07.2 Dr Google, Porn or Friend of a Friend? Where do young men get their sexual health information? <i>Amy Litras</i>
2.15pm–2.30pm	O05.3 Multiplex Real-Time PCR with High Resolution Melting Analysis for Detecting Resistance Mechanisms in <i>Neisseria gonorrhoeae</i> . <i>Valentina Dona</i>	2.15pm–2.30pm	O06.3 Host-Directed Therapeutics as Adjunctive Therapy for Antibiotic-Resistant <i>Neisseria gonorrhoeae</i> . <i>Isabelle Leduc</i>	2.15pm–2.30pm	O07.3 Detection of Hepatitis C Virus (HCV) in Semen From HIV-Infected Men Who Have Sex With Men (MSM) During Acute HCV Infection. <i>Samuel Turner (ISSTDR Scholarship)</i>	2.15pm–2.30pm	O08.3 Overlapping HIV and sex work stigma: Experiences from 14 sites across Zimbabwe. <i>James Hargreaves</i>			2.15pm–2.30pm	S07.3 High rates of chlamydia found among 12-16 year olds attending a rural sexual health clinic: Implications for practice <i>Jane Tomnay</i>
2.30pm–2.45pm	O05.4 Multiplex assay for simultaneous detection of <i>Mycoplasma genitalium</i> and macrolide resistance using PASS MNAzyme qPCR <i>Sepehr Tabrizi</i>	2.30pm–2.45pm	O06.4 Azithromycin Versus Doxycycline for Urogenital Chlamydia: A Randomized Clinical Trial in Females and Males in Youth Correctional Facilities. <i>William Geisler</i>	2.30pm–2.45pm	O07.4 Incident HIV Associated with Rectal Gonorrhoea (GC) and Chlamydia (CT) Independent of Sexual Behaviors in Men who have Sex with Men (MSM). <i>Matthew Golden</i>	2.30pm–2.45pm	O08.4 The ISEAN Hivos Stigma and Discrimination Study (SADS) in Health Care Settings (SADS-HCS-2015) in South East Asia Island Countries – Initial Findings From Indonesia. <i>Loyd Brendan P. Norella</i>	2.25pm–2.45pm	S06.3 <i>Chlamydia trachomatis</i> vaccine development: New tools bring new hope. <i>Peter Timms</i>	2.30pm–2.45pm	S07.4 Better, sooner, more convenient: Increasing youth friendliness of Family Planning Services in New Zealand. <i>Rose Stewart</i>

MONDAY 14 SEPTEMBER											
2.45pm–3.00pm	O05.5 <i>Treponema pallidum</i> Strain–Types in Australia and Association with Macrolide Resistance. <i>Philip Read</i>	2.45pm–3.00pm	O06.5 Periodic presumptive treatment for vaginal infections may reduce chlamydia and gonorrhoea incidence: A secondary analysis from the Preventing Vaginal Infections trial. <i>Jennifer Balkus</i>	2.45pm–3.00pm	O07.5 Sexual Risk Behaviour and Sexually Transmitted Diseases among Men Who Have Sex with Men Participating in a Pre-Exposure Prophylaxis Demonstration Project. <i>Stephanie Cohen</i>	2.45pm–3.00pm	O08.5 Our Voices, Our Communities, Our Rights. <i>Ken Moala (ISSTDR Scholarship)</i>	2.45pm–3.05pm	S06.4 New technology innovations and <i>Neisseria gonorrhoeae</i> vaccine development. <i>Scott Gray–Owen</i>	2.45pm–3.00pm	S07.5 Sociocultural context and sexual health information among adolescents and young adults. <i>Jami Leichter</i>
3.00pm–3.15pm	O05.6 Distinct growth and genome profiles are present in clinical isolates from women who fail to resolve genital chlamydia infection after Azithromycin treatment. <i>Wilhelmina Huston</i>	3.00pm–3.15pm	O06.1 The efficacy of pristinamycin for <i>Mycoplasma genitalium</i> an increasing multidrug resistant pathogen. <i>Catriona Bradshaw</i>	3.00pm–3.15pm	O07.6 Role of Minority Stress in Health–Risk Behaviors Among Young MSM & TGs in India. <i>Not presented</i>	3.00pm–3.15pm	O08.6 The Gendered Influence of Stigma on HIV Testing Behavior: Results from a Population-Based Survey of Women and Men in Rwanda. <i>Shari Krishnaratne</i>	3.05pm–3.15pm	STI vaccines: A call to action. <i>Helen Rees</i>	3.00pm–3.15pm	Q&A
3.15pm–3.45pm	Afternoon Tea and Poster Viewing in Exhibition Hall 1										
3.45pm–5.15pm	PL02 Plenary Session 2 – Great Hall 4 – Door 1 Foyer Chairs: <i>Mauro Romero Passos & Jackie Jennings</i>										
3.45pm–4.15pm	PL02.1 Falling between the gaps: An overview of issues for Aboriginal and Torres Strait Islander women who want to be sexually healthy. <i>Dr Kerry Arabena, Professor of Indigenous Health and Director, Indigenous Health Equity Unit, Centre for Health Equity, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia</i>										
4.15pm–4.45pm	PL02.2 The complex puzzle of BV and STI interactions <i>Dr Scott McClelland, Professor of Allergy and Infectious Diseases, School of Medicine, University of Washington, Seattle, USA</i>										
4.45pm–5.15pm	PL02.3 Syphilis elimination in China <i>Dr Yang Bin, Dean of Guangdong Provincial Dermatology Hospital / Director of Guangdong Provincial Centers for Skin Diseases and STI Control, and Professor, Jinan University, Guangdong Medical College, and Anhui Medical University, China</i>										
5.15pm–6.45pm	Evening Satellite – Cepheid. Room: M3 The Use of Rapid Diagnostics to Transform the Management of STDs <i>It's all about optimising patient care</i> <i>Moderator: Dr. Dave Persing, Chief Medical and Technology Officer, Cepheid</i> New CDC Guidelines and the Emerging Need for Rapid CT/NG Testing , Prof. Edward Hook University of Alabama at Birmingham, USA Live Demonstration: Rapid STI Screening with Xpert® CT/NG* , Dean Street Express: An Innovative Model of Sexual Health Care, Dr. Alan McOwan & Mr. Leigh Chislett Dean Street Express Clinic, Chelsea and Westminster NHS Trust, UK Use of Molecular Point-of-Care Tests to Reduce Sexually Transmissible Infections in a High Burden Setting , Dr. Rebecca Guy Kirby Institute, Sydney, Australia Panel Discussion					5.15pm–6.45pm	S08 New global health sector strategies for STI, HIV and viral hepatitis epidemics: changing the trajectories Room: M1 & M2 – Mezzanine Chair: <i>Helen Rees & David Lewis</i>				
		5.15pm–5.35pm	S08.1 WHO global highlights and challenges in relation to HIV, hepatitis and STIs. <i>Nathalie Broutet</i>								
		5.35pm–5.55pm	The 'What' and the 'How': Defining an essential package for maximum impact across full continuum and leveraging combination interventions. <i>Graeme Barden</i>								
		5.55pm–6.15pm	S08.3 Ensuring equity, realising rights, and promoting evidence: How can the new WHO strategies respect principles of equity and justice and still be effective? <i>Sarah Hawkes</i>								
		6.15pm–6.35pm	S08.4 What is "sustainable": The costs and cost-savings of strategies to expand services. <i>Jim Kahn</i>								
		6.35pm–6.45pm	Q&A								

MONDAY 14 SEPTEMBER											
6.00pm–8.00pm	ASHA Social Function – Hospitality Lounge – Exhibition Hall 1										
TUESDAY 15 SEPTEMBER											
7.00am	Registration opens										
7.30am–9.00am	Breakfast Educational Satellite – sponsored by Hologic New Developments in STI Diagnostics Featured Speakers: – Magnus Unemo – Paddy Horner – Philip Cunningham – Sepehr Tabrizi Room: Plaza Terrace Room, Plaza Level										
9.15am–10.45am	PL03 Plenary Session 3 – Great Hall 4 – Door 1 Foyer Chairs: <i>Nicola Low & Christopher Fairley</i>										
9.15am–9.45am	PL03.1 Advances in Chlamydia genetics – from understanding basic biology to vaccine design <i>Dr Raphael Valdivia, Associate Professor, Vice Dean for Basic Research, Duke University Medical Center, Durham, USA</i>										
9.45am–10.15am	PL03.2 Screening for chlamydia: does it work, results from ACCEPT <i>Dr Jane Hocking, Professor of Epidemiology, Centre for Women's Health, Gender and Society, University of Melbourne, Melbourne, Australia</i>										
10.15am–10.45am	Debate: Azithromycin should be abandoned as a treatment for bacterial STI (FOR: <i>Dr Paddy Horner, Bristol, UK</i> ; AGAINST: <i>Dr John Saunders, London, UK</i>)										
10.45am–11.15am	Morning Tea and Poster Viewing in Exhibition Hall 1										
11.15am–12.30pm	O09 Novel Methods for STI basic research Room: Great Hall 1 – Door 6 Mezzanine Chairs: <i>Peter Timms & Caroline Cameron</i>	11.15am–12.30pm	O10 <i>Trichomonas vaginalis</i> Room: Great Hall 2 – Door 8 Mezzanine Chairs: <i>Sharon Hillier & Sam Phiri</i>	11.15am–12.30pm	O11 Partners, places and STI risks Room: Great Hall 3 – Door 4 Foyer Chairs: <i>Immy Ahmed–Jushuf & Rebecca Guy</i>	11.15am–12.30pm	O12 Sexual health of sex workers Room: M1&2 Mezzanine Chairs: <i>Michel Alary & Janelle Fawkes</i>	11.15am–12.30pm	S09 Results from the Australian Chlamydia Control Effectiveness Pilot (ACCEPT) Room: Great Hall 4 – Door 1 Foyer Chairs: <i>Jane Hocking & Nicola Low</i>	11.15am–12.00pm	S10 Promoting STI control policies and programmes post–2015: Lessons for the future from Iran and China Room: Plaza Terrace Room, Plaza Level Chairs: <i>Monire Bassir & Sarah Hawkes</i>
11.15am–11.30am	O09.1 Standardized, Quality Assured Time-Kill Curve Analysis and Pharmacodynamic Functions of Different Antibiotics for in Vitro Evaluation of Treatment Regimens for <i>Neisseria gonorrhoeae</i> . <i>Sunniva Förster</i>	11.15am–11.30am	O10.1 TV In Primary Care: Is There More Out There Than You Think? <i>Jane Nicholls (ISSTDR Scholarship)</i>	11.15am–11.30am	O11.1 Patient–Delivered Partner Therapy (PDPT) Increases the Frequency of Partner Notification among MSM in Lima, Peru: A Randomized Clinical Trial. <i>Jesse Clark</i>	11.15am–11.30am	O12.1 'Tara Bandu', Social Values and Sex Work: The Interplay of Traditional Justice, Society and HIV/ STI Programming for Sex Workers in Timor-Leste. <i>David Fowler</i>	11.15am–11.30am	S09.1 How can chlamydia screening work in Australian general practice? <i>Meredith Temple-Smith</i>	11.15am–11.30am	S10.2 Keeping STIs on the agenda in Iran: Role of UNFPA. <i>Monire Bassir</i>

TUESDAY 15 SEPTEMBER											
11.30am–11.45am	O09.2 Establishment of the gonorrhea mouse model for pre-clinical testing of antimicrobial agents against <i>Neisseria gonorrhoeae</i> . <i>Kristie Connolly (ISSTDR Scholarship)</i>	11.30am–11.45am	O10.2 <i>Trichomonas vaginalis</i> nucleic acid clearance following treatment of HIV negative women. <i>David Martin</i>	11.30am–11.45am	O11.2 Overcoming the ambiguity of sexual partnership type: A novel categorisation using data from Britain's 3rd National Survey of Sexual Attitudes & Lifestyles (Natsal-3). <i>Cath Mercer</i>	11.30am–11.45am	O12.2 Understanding the Relationship Dynamics between Female Sex Workers and their Intimate Partners in Kumasi, Ghana. <i>Not presented</i>	11.30am–11.45am	S09.2 The prevalence of chlamydia among 16 to 29 year olds in Australia. <i>Alaina Vaisey</i>	11.30am–11.45am	S10.3 STI control in China: What accounts for political priorities? <i>Flora Wu</i>
11.45am–12.00pm	O09.3 Reliable genotypic tropism tests for the major HIV-1 subtypes. <i>Not presented</i>	11.45am–12.00pm	O10.3 Low effectiveness of syndromic diseases management in women infected with <i>Chlamydia trachomatis</i> , <i>Trichomonas vaginalis</i> and <i>Neisseria gonorrhoeae</i> leads in Delhi India <i>Subash Sonkar (ISSTDR Scholarship)</i>	11.45am–12.00pm	O11.3 <i>Trichomonas vaginalis</i> risk and cofactors among peripartum Kenyan women: protective association with male partner circumcision. <i>Jillian Pintye (ISSTDR Scholarship)</i>	11.45am–12.00pm	O12.3 Multicultural Survey – 20 Years On: Trends in Chinese and Thai Female Sex Worker Demographics and Sexual Health in Sydney. <i>Caroline Thng</i>	11.45am–12.00pm	S09.3 The impact of screening on chlamydia transmission in Australia – a mathematical modelling study. <i>David Regan & Ben Hui</i>	11.45am–12.00pm	Moderated panel discussion
12.00pm–12.15pm	O09.4 Estimating HSV-2 Superinfection using a Novel Custom Genotyping Platform. <i>Christine Johnston</i>	12.00pm–12.15pm	O10.4 Performance of Self-collected penile swabs for the detection of <i>Chlamydia trachomatis</i> , <i>Neisseria gonorrhoeae</i> , <i>Trichomonas vaginalis</i> , and <i>Mycoplasma genitalium</i> . <i>Charlotte Gaydos</i>	12.00pm–12.15pm	O11.4 Place and Core Transmitters – Implications for the Targeted Control of STI Transmission in Urban Areas. <i>Jackie Jennings</i>	12.00pm–12.15pm	O12.4 Impact and Cost-Effectiveness of HIV Prevention Interventions Among Transgender Women Sex-Workers in Lima, Peru Using Mathematical Modelling Informed By Stakeholder Analysis and Health-System Capacity Evaluation. <i>Carlos Cáceres</i>	12.00pm–12.15pm	S09.4 What does ACCEPt mean for chlamydia control policy? <i>Helen Ward</i>		
12.15pm–12.30pm	O09.5 Isolation and Amplification of Treponemal DNA for Whole Genome Sequencing Directly from the Patient Sample. <i>Linda Grillova (ISSTDR Scholarship)</i>	12.15pm–12.30pm	O10.5 Rapid Diagnosis of <i>Trichomonas vaginalis</i> by Testing Vaginal Swabs in an Isothermal Helicase-Dependent AmpliVue Assay. <i>Max Chernesky</i>	12.15pm–12.30pm	O11.5 Incorporating Spatial Variability to Generate Sub-National Estimates of HIV Prevalence. <i>Diego Cuadros</i>	12.15pm–12.30pm	O12.5 Behavioural interventions improve condom use and HIV testing uptake among female sex workers in China: A systematic review and meta-analysis. <i>Eric Chow</i>	12.15pm–12.30pm	Q&A		
12.30pm–2.00pm	ASTDA Luncheon – Plaza Terrace Room, Plaza Level Distinguished Career Award: Anna Wald, MD, MPH Achievement Award: Jeanne Marrazzo, MD, MPH Young Investigator Award: Robert Kirkcaldy, MD, MPH										
12.30pm–2.00pm	Lunch and Poster Viewing in Exhibition Hall 1										
1.30pm–2.00pm	IUSTI World General Assembly – Hospitality Lounge, Exhibition Hall 1 Mezzanine										

TUESDAY 15 SEPTEMBER											
2.00pm–3.30pm	O13 Vaginal health and the microbiome Room: Great Hall 1 – Door 6 Mezzanine Chairs: Anna Wald & Jørgen Jensen	2.00pm–3.30pm	O14 Increasing access to and uptake of sexual health care Room: Great Hall 2 – Door 8 Mezzanine Chairs: Angelica Espinosa Miranda & Edward Hook III	2.00pm–3.30pm	O15 Chlamydia infections Room: Great Hall 3 – Door 4 Foyer Chairs: Max Chernesky & Julius Schachter	2.00pm–3.30pm	O16 HPV Vaccination: Hits and misses Room: M1&2 – Mezzanine Chairs: Shailendra Sawleshwarkar & Elizabeth Torrone	2.00pm–3.30pm	S11 Molecular aspects of antimicrobial resistant <i>Neisseria gonorrhoeae</i> Room: Great Hall 4 – Door 1 Foyer Chairs: Monica Lahra & William Shafer	2.00pm–3.30pm	S12 Sexual health issues for Indigenous youth in Australia and New Zealand Room: Plaza Terrace Room, Plaza Level Chairs: Andrew Valley & Jami Leichter
2.00pm–2.15pm	O13.1 The Broad Diversity of Cultivable Microbiota in Pregnant Women and the Detection of Novel Organisms. <i>Sharon Hillier</i>	2.00pm–2.15pm	O14.1 Is an automated online clinical care pathway for people with genital chlamydia (chlamydia-OCCP) within an esexual health clinic feasible and acceptable? proof of concept study. <i>Claudia Estcourt</i>	2.00pm–2.15pm	O15.1 Sensitive Detection of <i>Chlamydia trachomatis</i> Pgp3 Antibody Demonstrates Antibody Persistence and Correlates with Self-Reported Infection and Behavioural Risks in a Blinded Cohort Study. <i>Paddy Horner</i>	2.00pm–2.15pm	O16.5 Health Care Attendance among Aboriginal Youth Aged 15-19 years old Provides Opportunities to Improve Human Papilloma Virus (HPV) Vaccination Coverage. <i>Marlene Kong</i>	2.00pm–2.20pm	S11.1 Real-time PCR detection of <i>N. gonorrhoeae</i> resistance: where are we now? <i>David Whaley</i>	2.00pm–2.10pm	The epidemiology of STIs in young indigenous people in Australia and New Zealand. <i>James Ward</i>
									2.10pm–2.25pm	S12.1 What do young Indigenous people tell us about sexual health? Finding from two national surveys in Australia and New Zealand. <i>Terryann Clark</i>	
2.15pm–2.30pm	O13.2 Hormonal Contraception is Associated with Stability and Lactobacillus-Dominance of the Vaginal Microbiota in a Two-Year Observational Study. <i>Rebecca Brotman</i>	2.15pm–2.30pm	O14.2 Good Call! Implementation of a Regional Online and Toll-Free STD Clinical Consultation Program. <i>Kees Rietmeijer</i>	2.15pm–2.30pm	O15.2 Combined Detection of Chlamydia, Gonorrhoea and Trichomonas using the BD MAXTM CT/GC/TV Assay. <i>Barbara Van Der Pol</i>	2.15pm–2.30pm	O16.1 The rapid and near elimination of human papillomavirus (HPV) type 6, 11, 16 and 18 among young high-risk women within three years of the national HPV vaccination programme in Australia: Findings from a 10-year cross-sectional study. <i>Eric Chow</i>	2.20pm–2.40pm	S11.2 Efflux pumps in <i>N. gonorrhoeae</i> – cause of resistance and targets for therapeutics and vaccine? <i>William Shafer</i>	2.25pm–2.40pm	Supporting primary health services to address high rates of sexually transmissible infections; findings from the STRIVE trials. <i>James Ward</i>
2.30pm–2.45pm	O13.3 The Impact of Vaginal Bacterial Biofilm on Intravaginal Rings. <i>Liselotte Hardy (ISSTDR Scholarship)</i>	2.30pm–2.45pm	O14.3 Referring Clinic Turn-Aways to British Columbia's Internet-Based Testing Program Getcheckedonline to Increase Capacity for Timely STI/HIV Testing. <i>Devon Haag</i>	2.30pm–2.45pm	O15.3 High Chlamydia Treatment Failure Rates in Men Who Have Sex With Men. <i>Kirsty Smith (ISSTDR Scholarship)</i>	2.30pm–2.45pm	O16.2 Evidence, Politics and Cultures in Policymaking: Policy Analysis of HPV Vaccine Introduction in India. <i>Sathyanarayan Tamsetty (ISSTDR Scholarship)</i>	2.40pm–3.00pm	S11.3 Use of whole genome sequencing to determine the probability of antimicrobial resistance in <i>N. gonorrhoeae</i> . <i>David Trees</i>	2.40pm–2.55pm	TTANGO (Test, Treat and Go); use of molecular point-of-care tests to detect and treat sexually transmissible infections in young Aboriginal people in remote communities <i>Corine Swan and Rebecca Guy</i>

TUESDAY 15 SEPTEMBER											
2.45pm–3.00pm	O13.4 Cervicovaginal microbiome dysbiosis is associated with proteome changes related to alterations of the cervico-vaginal mucosal barrier. <i>Hanneke Borgdorff (ISSTDR Scholarship)</i>	2.45pm–3.00pm	O14.4 Home-Based Specimen Collection for <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> Testing Does Not Improve Clinical Management Outcomes: Systematic Review. <i>Nicola Low</i>	2.45pm–3.00pm	O15.4 Azithromycin treatment failure in women infected with genital chlamydia infection. <i>Jane Hocking</i>	2.45pm–3.00pm	O16.3 HPV vaccine introduction in Thailand. <i>Worawan Klinsupa.</i>	3.00pm–3.20pm	Molecular methods for <i>N. gonorrhoeae</i> antimicrobial resistance prediction, epidemiology and public health – future perspectives. <i>Magnus Unemo</i>	2.55pm–3.10pm	Capacity building of young Aboriginal health workers in health promotion improves the sexual health of their peers. <i>Marlene Kong</i>
3.00pm–3.15pm	O13.5 Association Between Dietary Intake and Dysbiotic Vaginal Microbiota. <i>Susan Tuddenham</i>	3.00pm–3.15pm	O14.6 Attributes of Diagnostic Tests to Increase Uptake of Testing For Syphilis and HIV in Port-Au-Prince, Haiti. <i>Jeff Klausner</i>	3.00pm–3.15pm	O15.5 The Natural History of <i>Chlamydia trachomatis</i> Infection in Women: A Multi-Parameter Evidence Synthesis. <i>Malcolm Price</i>	3.00pm–3.15pm	O16.4 The Estimated Impact and Cost-Effectiveness of Nonavalent HPV Vaccination in the United States. <i>Harrell Chesson</i>	3.10pm–3.30pm	Moderated Panel Discussion		
3.15pm–3.30pm	O13.6 Cigarette smoking is associated with an altered metabolic profile in the vaginal tract <i>Joanna Borgogna</i>	3.15pm–3.30pm	O14.5 Blind Spot on Heterosexual Men? Multiple Pathways to STI Care Among Men in Malawi. <i>Sarah Hawkes</i>	3.15pm–3.30pm	O15.6 Impact of The LNG-IUS on Cervical Persistence of <i>Chlamydia trachomatis</i> and Vaginal Microbiota in a Baboon Model. <i>Jason Bell</i>	3.15pm–3.30pm	O16.6 General Practitioner Awareness of Sexual Orientation in a Community and Internet Sample of Gay and Bisexual Men in New Zealand: Implications for HPV Vaccination. <i>Adrian Ludlam (ISSTDR Scholarship)</i>	3.20pm–3.30pm	Q&A		
3.30pm–4.00pm	Afternoon Tea and Poster Viewing in Exhibition Hall 1										
4.00pm–5.30pm	PL04 Plenary Session 4 – Great Hall 4 – Door 1 Foyer Chairs: <i>Tom Quinn & Roy Chan</i>										
4.00pm–4.30pm	PI04.1 Male circumcision for STI prevention –how well does it work and how is it done? <i>Dr Kawango Agot, Professor, University of Nairobi and CEO, Impact Research & Development Organization, Kenya</i>										
4.30pm–5.00pm	PI04.2 Where are the men? STI and sexual health services for men <i>Dr Ravi Verma, Regional Director and Madhumita Das, International Centre for Research on Women, New Delhi, India</i>										
5.00pm–5.30pm	PL04.3 Sexually transmitted infections in men who have sex with men <i>Dr Henry J C de Vries, Professor of Skin Infections, STI outpatient clinic, Public Health Service Amsterdam, Department of Dermatology, and CINIMA, Academic Medical Center, University of Amsterdam, and Centre for Infectious Diseases Control, National Institute for Public Health and the Environment (CIb/RIVM), Bilthoven, The Netherlands</i>										

TUESDAY 15 SEPTEMBER			
5.30pm–8.00pm	5.30pm – 8.00pm Satellite Session: Community PrEP Forum by the HIV Foundation QLD Room: M1&2 Mezzanine Facilitator: <i>Heath Paynter</i>	5.30pm–7.00pm	S13 Microbiome of the genital tract, host immune responses and STI interactions Room: Plaza Terrace Room, Plaza Level Chairs: <i>Jo-Ann Passmore & David Martin</i>
5.30pm–6.00pm	Refreshments served outside the room	5.30pm–5.50pm	S13.1 The many facets of the vaginal microbiome in health and disease <i>Jacques Ravel</i>
6.00pm–6.10pm	Opening – <i>Dr Jeannette Young, Chief Health Officer</i> Welcome to Country – <i>Aunty Carol Currie</i>	5.50pm–6.10pm	S13.2 Genital immunology, the microbiota and HIV transmission <i>Rupert Kaul</i>
6.10pm–6.40pm	Hear how PrEP has changed HIV in San Francisco from the man who led the way: <i>Professor Bob Grant</i>	6.10pm–6.30pm	S13.3 Penile microbiota. <i>Cindy Liu</i>
6.40pm–6.55pm	What is it like to be on PrEP? <i>Chris Williams</i>	6.30pm–6.50pm	S13.4 The vaginal microbiome and STI. <i>Janneke van de Wijgert</i>
6.55pm–7.05pm	PrEP in Australia and Queensland 2015 <i>Dr Darren Russell</i>	6.50pm–7.00pm	Q&A
7.05pm–8.00pm	Your questions answered – Panel: <i>Professor Bob Grant, Dr Darren Russell, Dr Fiona Bisshop, Mr Heath Paynter, Chris Williams</i>		

WEDNESDAY 16 SEPTEMBER

6.30am	Registration opens					
7.00am – 8.45am	ART perspectives symposium breakfast session sponsored by ViiV Healthcare Room: M3, Mezzanine Level		Penelope Lowe Trainee Breakfast Room: M1 & M2 Mezzanine Level		The Australian Sexual Health and HIV Nurses Association (ASHHNA) Breakfast- sponsored by Gilead Rydges Hotel, accessible from Plaza Level, Brisbane Convention Centre	
9.00am – 10.45am	PL05 World STI & HIV Congress Plenary Session 5 and Opening Plenary Australasian HIV&AIDS Conference 2015 - supported by the Department of Health Australia Room: Great Hall 4, Door 1 Foyer (Overflow: Great Hall 1, Door 6) Chairs: Charles Gilks & Jeanne Marrazzo					
9.00am – 9.05am	Welcome to Country Aunty Carol Currie Traditional owner Jagera					
9.05am – 9.06am	Conference Convenor Welcome Professor Charles Gilks, Head of School & HIV/STI Prof Chair, School of Public Health, Faculty of Medicine and Biomedical Sciences, University of QLD, Australia					
9.06am – 9.11am	Welcome Hon Cameron Dick MP, Minister for Health, Minister for Ambulance Services, QLD, Australia					
9.11am – 9.15am	Welcome to Australian HIV Conference on behalf of people with HIV and HIV NGO Sector: Robert Mitchell, President, NAPWHA, National Association of people with HIV Australia, Bridget Haire, President, AFAO, Australian Federation of AIDS Organisations					
9.15am – 9.45am	PL05.1 Treatment to prevent HIV: does timing matter? Professor Myron S. Cohen, Associate Vice Chancellor for Global Health, Yergan-Bate Distinguished Professor of Medicine, Microbiology and Immunology, University of North Carolina at Chapel Hill, USA					
9.45am – 10.15am	PL05.2 Why STI-associated genital tract inflammation still matters in HIV transmission Dr. Jo-Ann Passmore, Associate Professor, Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Centre for the AIDS Programme of Research in South Africa (CAPRISA), National Health Laboratory Service, South Africa					
10.15am – 10.45am	PL05.3 HIV and Syphilis: a syndemic with no end in sight Dr Phillip Read, Sexual Health Physician, Kirketon Road Centre, Sydney, NSW, Australia					
10.45am – 11.15am	Morning Tea and Poster Viewing in Exhibition Hall 1					
11.15am – 12.45pm	O17 Advances in HIV and HTLV-1 Room: Great Hall 1 - Door 6 Mezzanine Chairs: TonyCunningham & John Zaunders	11.15am - 12.45pm O18 HIV and Women's Health Room: Great Hall 2 - Door 8 Mezzanine Chairs: Jackie Cassell & Rebecca Guy	11.15am - 12.45pm O19 Evaluating PrEP and HIV treatment as prevention in Australia Room: Great Hall 3 - Door 4 Foyer Chairs: William Smith & Edwina Wright	11.15am - 12.45pm O20 HIV Transmission in MSM Room: Great Hall 4 - Door 1 Foyer Chairs: Henry de Vries & David Cooper	11.15am - 12.45pm S14 Causal interactions among structural, behavioural and biological drivers of STD/HIV epidemics Room: M3 - Mezzanine Chairs: Sevgi Aral & Catriona Bradshaw	11.15am - 12.45pm S15 Multipurpose Technologies (MPTs): Developing interventions to simultaneously prevent STIs, HIV and pregnancy (WHO/IMPT/ASHA) Room: M1&2- Mezzanine Chairs: Anke Hemmerling & Carolyn Deal
11.15am – 11.30am	O17.1 Histone Deacetylase Inhibitors Alter the Accumulation of Cell-Associated Spliced HIV MRNA – Implications for Reactivating the Reservoir Talia Mota (ISSTD Scholarship)	11.15am – 11.30am O18.1 Prevalence and Factors Associated with Modern Contraceptive use among HIV - Positive Women Aged 15–49 Years in Kilimanjaro Region, Northern Tanzania Damian Jeremia (ISSTD Scholarship)	11.15am – 11.30am O19.1 Preexposure Prophylaxis of HIV (PrEP): Utilisation Estimates in Australia Iryna Zablotska	11.15am – 11.30am O20.1 The Challenges of Diversity: HIV-1 Subtype Distribution and Transmission Networks within the Australian Molecular Epidemiology Network-HIV 2005-2012 Alison Castley (ISSTD Scholarship)	11.15am – 11.30am S14.1 Transitions around sex work and their significance in STI/HIV epidemics Eve Cheuk	11.15am – 11.35am Overview and pipeline of MPTs relevant to the prevention of STIs Vivian Black

WEDNESDAY 16 SEPTEMBER

11.30am – 11.45am	O17.2 Characterizing Clade-Specific Virus-Host Interactions in HIV Infected Clinically Asymptomatic and AIDS Presenting Subjects Abhilasha Mathur	11.30am – 11.45am O18.2 Injectable Progestin Contraception and Acquisition of HSV-2 Infection among South African Women Participating in the VOICE Trial Lisa Noguchi	11.30am – 11.45am O19.2 Pre-exposure Prophylaxis and Risk Compensation: Evidence of Decreased Condom use at Three-month Follow-up Among Predominantly Gay Male Participants in the VicPrEP Study John de Wit	11.30am – 11.45am O20.2 HIV-1 Sequence Diversity and Transmission Networks in Western Australia from 2000-2014, and their Impact on Baseline Clinical Characteristics Alison Castley (ISSTD Scholarship)	11.30am – 11.45am S14.2 Age, sexual experience and mucosal inflammation: What do we know? Lyle McKinnon	11.35am – 11.55am S15.2 Global mapping of STIs, HIV and unplanned pregnancy: Where do these epidemics intersect? Erin Schelar
11.45am – 12.00pm	O17.3 IL-4/IL-13 Inhibitor Vaccines Induce Protective Immunity by Modulating Innate Lymphocytic, Dendritic and Macrophage Cell Subsets at the Vaccination Site Charani Ranasinghe	11.45am – 12.00pm O18.3 Adolescents in South Africa and Assessment of HIV Risk: Knowing Who We Are Trying to Protect Shaun Barnabas (ISSTD Scholarship)	11.45am – 12.00pm O19.3 Pills, Pleasure and Privacy: Early Experiences of Pre-Exposure Prophylaxis among Men in the VicPrEP Study John de Wit	11.45am – 12.00pm O20.3 HIV Transmission in Male Serodiscordant Couples in Australia, Thailand and Brazil Ben Bavinton	11.45am – 12.00pm S14.3 Immune activation, gene expression and HIV acquisition risk Keith Fowke	11.55am – 12.15pm S15.3 Making the case for MPTs: Prevention of infertility and other STI sequelae Okeoma Mremeje
12.00pm – 12.15pm	O17.4 Development and Validation of a Human T-Cell Lymphotropic Virus Type-1 Proviral Load Assay Kim Wilson	12.00pm – 12.15pm O18.4 Sex Differences in HIV Knowledge, Testing Behaviors, and Decision Making Influences in Rural Malawi Alison Norris	12.00pm – 12.15pm O19.4 Awareness and Interpretation of the Ending HIV Campaign and Changing Attitudes About Treatment as Prevention in an Online Cohort Of MSM. Jason Asselin	12.00pm – 12.15pm O20.4 Transmission Risk Beliefs Influence Sexual Risk Behavior of HIV-Positive MSM Hong-Ha Truong	12.00pm – 12.15pm S14.4 Phylogenetics and transmission patterns Not Presented	12.15pm – 12.35pm S15.4 The unmet need and potential application of MPTs for rectal use: Implications for women and MSM at risk of STIs and HIV Bridget Haire
12.15pm – 12.30pm	O17.5 Increased Herpes Simplex Virus-2 Shedding in HIV-1 Infected Persons is due to Poor Immunologic Control in both Ganglia and Genital Mucosa Joshua Schiffer	12.15pm – 12.30pm O18.5 Examining HPV prevalence and uptake of cervical cancer screening among HIV positive and negative women participating in a pilot RCT in Uganda comparing self-collection based HPV testing to VIA Sheona Mitchell-Foster	12.15pm – 12.30pm O19.5 Does 'Treatment as Prevention' Jeopardise Condom use Amongst Gay Men? An Analysis of Gay Men's Attitudes in NSW over Two Years Karen Price	12.15pm – 12.30pm O20.5 Trends in Undiagnosed HIV and HIV Testing Behaviour in Community Samples of Men Who Have Sex With Men in London, UK: Results From Repeat Cross-Sectional Surveys Between 2000-2013 Sonali Wayal	12.15pm – 12.30pm S14.5 Discussion: What does the mega model look like? James Blanchard	12.35pm – 12.45pm Q&A
12.30pm – 12.45pm	Q&A	12.30pm – 12.45pm O18.6 A Method to Estimate the National Prevalence of HIV-Infection Among Female Sex Workers in Zimbabwe by Pooling Data from Multiple Respondent Driven Sampling Surveys and Programme Consultations Elizabeth Fearon	Q&A	12.30pm – 12.45pm O20.6 First Forced Sex and Sexual Behaviour Affecting Prevalence of HIV/AIDS among MSM in South India Rakesh Singh (ISSTD Scholarship)	Q&A	
12.45pm – 1.45pm	Lunch and Poster Viewing in Exhibition Hall 1					

WEDNESDAY 16 SEPTEMBER											
12.45pm–1.30pm	The Kirby Institute and Centre for Social Research in Health Surveillance Reports Information Session Room: M1&2, Mezzanine										
12.45pm–1.30pm	Film and Panel - Poz and Neg Action on PrEP: breaking down the stigma Hospitality Lounge, Exhibition Hall 1										
1.45pm–3.15pm	O21 HIV and Co-morbidity	1.45pm–3.15pm	Ending Hepatitis C in Populations	1.45pm–3.15pm	O23 HIV Epidemiology and Prevention	1.45pm–3.15pm	LB Late Breaker Session	1.45pm–3.15pm	S16 Sexually Transmitted Infections and HIV in Pregnancy	1.45pm–3.15pm	S17 HPV and HIV: New Evidence on the Infection Risks and Strategies to Prevention HPV-related Disease among HIV-infected People
	Room: Great Hall 1 - Door 6 Mezzanine Chairs: <i>Graham Nielsen & Winnie Tong</i>		Room: Great Hall 2 - Door 8 Mezzanine Chairs: <i>Gail Matthews & Graeme Macdonald</i>		Room: Great Hall 3 - Door 4 Foyer Chairs: <i>Lisa Manhart & John Kaldor</i>		Room: Great Hall 4 - Door 1 Foyer Chairs: <i>Hunter Handfield & Anne Johnson</i>		Room: M3 - Mezzanine Chairs: <i>Jeffrey Klausner & Mary Kamb</i>		Room: M1&2 - Mezzanine Chairs: <i>Craig Cohen & Richard Hillman</i>
1.45pm–2.00pm	HIV and CVD - do we really understand the risk? <i>Dr Patrick (Paddy) Mallon, Associate Dean for Research and Innovation, School of Medicine and Medical Science, University College Dublin (UCD), Ireland</i>	1.45pm–2.00pm	Control and Eradication within Australia of Hepatitis C from people living with HIV: the CEASE project <i>Associate Professor Gail Matthews, NHMRC fellow, Viral Hepatitis Clinical Research Program, The Kirby Institute, Sydney, NSW, Australia</i>	1.45pm–2.00pm	O23.1 Decreases in HIV prevalence in patients attending an inner-city emergency department over a decade correlate with trends in HCV but not HSV-2 <i>Thomas Quinn</i>	1.45pm–2.00pm	LB1.1 Randomised Controlled Trial Of A Complex Intervention To Improve School-Based HPV Vaccination For Adolescents: The HPV. EDU Study <i>Cristyn Davies</i>	1.45pm–2.05pm	S16.1 Eliminating mother to child transmission of HIV and syphilis <i>Maria Lantero</i>	1.45pm–2.05pm	S17.1 The evaluation of screening, treatment and vaccination of HIV-infected women <i>Jennifer Smith</i>
2.00pm–2.15pm	O21.1 Platelet Derived Soluble Glycoprotein VI Decreases Prior to Coronary Event in HIV Positive Patients <i>Janine Trevillyan</i>	2.00pm–2.15pm	HCV treatment as prevention in prisons: SToP-C study <i>Professor Gregory Dore, Head, Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW; Infectious Diseases Physician, St Vincent's Hospital, Sydney, NSW, Australia</i>	2.00pm–2.15pm	O23.2 Achieving the goals of the U.S. national HIV/AIDS strategy: Declining HIV diagnoses, improving clinical outcomes, and diminishing racial/ethnic disparities in King County, WA., USA <i>Matthew Golden</i>	2.00pm–2.15pm	LB1.2 Pilot study of immediate antiretrovirals and behavioral intervention for persons with acute HIV infection: Opportunity for interrupting transmission <i>William Miller</i>	2.05pm–2.25pm	S16.2 Potential for uptake of diagnostic testing services along the continuum of care: Landscape assessment of community and providers <i>Sadaf Khan</i>	2.05pm–2.25pm	S17.2 HPV infection, genital inflammation, and HIV risk in the CAPRISA 004 trial <i>Lenine Liebenberg</i>
2.15pm–2.30pm	O21.2 One Profile or Many? Plasma Biomarkers CXCL10, sCD163 and sCD14 Reveal Distinct Associations with HIV Treatment Response, Choice of Treatment Regimen, and Cardiovascular Risk Factors <i>David Nolan</i>	2.15pm–2.30pm	Treatment and prevention to eliminate hepatitis C. The TAP Study <i>Professor Margaret Hellard, Head, Centre for Population Health, Burnet Institute; Head, Hepatitis Services, Infectious Diseases Unit, The Alfred Hospital; Adjunct Professor, Infectious Diseases Epidemiology, Monash University, Melbourne, VIC, Australia</i>	2.15pm–2.30pm	Rapid HIV testing increases testing frequency among gay and bisexual men: a controlled before-after study <i>Phillip Keen</i>	2.15pm–2.30pm	LB1.3 The Impact of HPV Vaccination On Genital Warts In Aboriginal Australians: Analysis of National Data <i>Hammad Ali</i>	2.25pm–2.45pm	S16.3 Clinical management of STI in pregnancy <i>John Kinuthia</i>	2.25pm–2.45pm	S17.3 Novel therapies for HPV-related anal disease <i>Henry de Vries</i>

WEDNESDAY 16 SEPTEMBER											
2.30pm–2.45pm	O21.3 Pre-Therapy Inflammation/ Coagulation Activation and Long-Term CD4 Response to Antiretroviral Therapy <i>Amit Achhra</i>	2.30pm–2.45pm	Management of co-occurring HCV and substance use disorder, challenges and opportunities <i>Associate Professor Nadine Ezard, Clinical Director, Alcohol and Drug Service, St Vincent's Hospital Sydney, NSW, Australia</i>	2.30pm–2.45pm	The HIV Cascade: a review of methodology and data sources <i>Dr Nick Medland, Sexual Health Physician, Melbourne Sexual Health Centre, Royal Melbourne Hospital, Doctoral Research Scholar, Monash University, Melbourne, VIC, Australia</i>	2.30pm–2.45pm	LB1.4 STI Rates among Gay Men Taking Daily Antiretrovirals For Pre-Exposure Prophylaxis Of HIV: The NSW Demonstration Project PRELUDE <i>Iryna Zablotska</i>	2.45pm–3.05pm	S16.4 Point-of-care testing and treatment of sexually transmitted infections to improve pregnancy outcomes in high-burden settings <i>Andrew Vallely</i>	2.45pm–3.05pm	S17.4 Using data on pathogenesis and epidemiology to inform anal cancer screening strategies: data from the Study of Prevention of Anal Cancer (SPANC) <i>Mary Poynten</i>
2.45pm–3.00pm	O21.4 Decreased Cellular Energy in the Brain Frontal White Matter is Associated with Past Immunosuppression in Chronic HIV Infection <i>Lucette Cysique</i>	2.45pm–3.15pm	Panel Discussion <i>Greg Dore, Margaret Hellard, Gail Matthews, Nadine Ezard, Graeme Macdonald, and David Pieper</i>	2.45pm–3.00pm	Working towards the virtual elimination of HIV transmission in NSW by 2020 <i>Dr Kerry Chant PSM, Chief Health Officer and Deputy Secretary Population and Public Health, NSW Ministry of Health, NSW, Australia</i>	2.45pm–3.00pm	LB1.5 Initial Interactions Of Herpes Simplex Virus With Human Skin Dendritic Cells <i>Tony Cunningham</i>	3.05pm–3.15pm	Q&A	3.05pm–3.15pm	Q&A
3.00pm–3.15pm	O22.2 Detection of Hepatitis C Virus (HCV) in semen from HIV-infected men who have sex with men (MSM) during acute HCV infection <i>Samuel Turner</i>	3.00pm–3.15pm	Q&A	3.00pm–3.15pm	LB1.6 Diagnostic test accuracy of the Alere Pima POC CD4 analyzer (PimaTM) in field settings: A meta-analysis <i>Minh Duc Pham</i>						
3.15pm–3.45pm	Afternoon Tea and Poster Viewing in Exhibition Hall 1										
3.45pm–5.15pm	PL06 World STI & HIV Congress Plenary 6 and Closing Ceremony Room: Great Hall 3 - Door 4 Foyer Level Chairs: <i>Matthew Golden & Janet Wilson</i>					3.45pm–5.15pm	Australasian HIV & AIDS Conference Plenary Room: Great Hall 4 - Door 1 Foyer Level Chairs: <i>Levinia Crooks and Mike Cohen</i>				
3.45pm–4.15pm	PL06.1 Legal and Rights aspects of HIV and STI <i>Dr. Carlos Cáceres, Professor of Public Health and Director, Center for Interdisciplinary Studies in Sexuality, AIDS and Society, Cayetano Heredia University, Lima, Peru</i>					3.45pm–4.15pm	Controlling HIV in the Asia Pacific Region: How much more needs to be done? (Theme C) <i>Professor John Kaldor, Professor and Program Head, The Kirby Institute, NSW, Australia</i>				
4.15pm–4.45pm	Debate: Penicillin caused the AIDS pandemic <i>(For: Dr. Andrew Francis-Tan, Atlanta, USA; Against: Professor Jeffrey Klausner, Los Angeles, USA)</i>					4.15pm–4.45pm	Excessive intellectual property protection for HIV treatments: the momentum for reform (Theme D) <i>Charles Chauvel, Team Leader, Inclusive Political Processes, Bureau for Policy & Programme Support, United Nations Development Programme, New York, USA</i>				
4.45pm–5.15pm	Closing presentation					4.45pm–5.15pm	Finding our way out of the HIV epidemic (Theme B and C) <i>Professor Robert Grant, Professor of Medicine, University of California, San Francisco., USA</i>				
						5.20pm–6.45pm	Panel Discussion - Find me, Treat me, PrEP me, Heal me (Courtesy of Tommy) Room: Great Hall 4, Door 1, Foyer Level Facilitator: Matt Wordsworth, ABC <i>Professor Robert Grant, Professor Mike Cohen, Professor Brian Gazzard, Associate Professor Edwina Wright, Dr Mark Bloch, Nicholas Parkhill, Professor Sharon Lewin, Nic Holas, Simon Ruth</i>				
7.30pm - 11.00pm	Joint Conference Dinner – City Hall Brisbane										

THURSDAY 17 SEPTEMBER					
7.30am	Registration opens				
8.30am – 10.30am	Plenary 2 Room: Great Hall 4, Door 1, Foyer Level Chairs: Sharon Lewin and Robert Grant				
8.30am – 9.00am	HIV-1 transmission - Lessons from heterosexual couples in Africa (Theme A) <i>Dr Eric Hunter, Professor of Pathology & Laboratory Medicine, Emory University, Centre for AIDS Research, Atlanta, USA</i>				
9.00am – 9.30am	Using DAA therapy to eliminate HCV – reality or dream? (Theme B) <i>Professor Edward Gane, Professor of Medicine, University of Auckland; Deputy Director, New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand</i>				
9.30am – 10.00am	New Technologies and Innovative Methods to Facilitate HIV Prevention, Testing and Care (Theme C) <i>Jeffery Klausner, Professor of Medicine and Public Health, UCLA Center for World Health, USA</i>				
10.00am – 10.30am	FastTrack the MSM Response in Asia! (Theme D) <i>Midnight Poonkasetwattana, Executive Director, APCOM (Asia Pacific Coalition on Male Sexual Health), Bangkok, Thailand</i>				
10.30am – 11.00am	Morning Tea and Poster Viewing in Exhibition Hall 1				
10.30am – 11.00am	AFAO Community and Advocacy Hub - Exhibition Hall <i>Biomedical update: AFAO and HIV Australia Launch: Expanded horizons for HIV treatment and prevention</i>				
11.00am – 12.35pm	Theme A - Interferons/ Inflammation Room: Great Hall 1, Door 6, Mezzanine Level Chairs: Tony Kelleher and Patricia Price	Theme B - ARV Guidelines Session 1 - When and What to Start Room: Great Hall 2, Door 8, Mezzanine Level Chairs: Julian Elliott	Theme C - HIV Epidemiology in the Region Room: Great Hall 3, Door 4, Foyer Level Chairs: Andrew Vallely and Catherine O'Connor	Theme D - Criminalisation Room: Great Hall 4, Door 1, Foyer Level Chairs: Bridget Haire and Sharna Quigely	Satellite Session - Undiagnosed HIV among Australian gay and bisexual men: Results from the COUNT study Room: M1&2, Mezzanine Level Chairs: John de Wit and Garrett Prestage
11.00am – 11.20am	Bone marrow transplantation, GVHD and HIV <i>Professor Geoff Hill, NHMRC Australia and QLD Health Senior Clinical Research Fellow. Director of Research, Cancer Care Services Brisbane, QLD, Australia</i>	Strategic Timing of AntiRetroviral Treatment (START) Study - Primary Results <i>Professor Jennifer Hoy, Director HIV Medicine, Alfred Hospital and Monash University, Melbourne, Victoria, Australia</i>	Survival Trends for HIV+ Patients Receiving First Line ART from the TREAT Asia HIV Observational Database (TAHOD-LITE) (466) <i>Nicole De La Mata</i>	Continuing to punish vulnerability: The futility of criminalisation <i>Charles Chauvel, Team Leader, Inclusive Political Processes, Bureau for Policy & Programme Support, United Nations Development Programme, New York, USA</i>	The prevalence and correlates of undiagnosed HIV among Australian gay and bisexual men <i>Martin Holt</i>
11.20am – 11.40am	Understanding and measuring the footprint of CMV in a positive life <i>Associate Professor Patricia Price, Principal Research Fellow, Curtin University, WA, Australia</i>	When to start <i>Dr Julian Elliott, Head of Clinical Research, The Alfred Hospital Infectious Diseases Unit, Melbourne, VIC, Australia</i>	Sexual Behaviour, Condom Use and HIV Prevalence in Remote Areas of Papua New Guinea (997) <i>Kevin Miles</i>	Danger! Danger! Criminal endangerment offences are an obstacle to the HIV response <i>Paul Kidd, Chair, Victorian HIV Legal Working Group, Past President, Living Positive VIC, Australia</i>	A tale of two studies – assessing results from two studies of undiagnosed HIV among gay and bisexual men in Melbourne in 2008 and 2014 <i>Jason Asselin</i>

THURSDAY 17 SEPTEMBER					
11.40am – 12.00pm	HIV-related innate immune imprinting persists in HIV patients receiving antiretroviral therapy <i>Associate Professor Anthony Jaworowski, Head, Jaworowski Laboratory & Principal Fellow, Burnet Institute, VIC, Australia</i>	What to start? HIV integrase inhibitors in initial therapy <i>Associate Professor Mark Boyd, Senior NHMRC Research Fellow, The Kirby Institute; Consultant HIV Physician, The Albion Centre and Holdsworth House; President, ASHM; Sydney, NSW, Australia</i>	Integrating Couple HIV Counseling and Testing (CHCT) on Ante Natal Care (ANC) service in Bali - Indonesia (312) <i>Ni Wayan Septarini</i>	Trafficking in Persons protocols - what effect do they have on sex work and HIV prevention in the Pacific <i>Professor Heather Worth, Chair, UNSW Human Research Ethics Committee; Director, GlobalHealth@UNSW; Director, International HIV Research Group, UNSW, Australia</i>	Comparing behavioural and demographic characteristics of gay and bisexual men in Australia with undiagnosed HIV infection with those recently diagnosed <i>Ian Down</i>
		What to Start: A broader look from the Australian perspective <i>Dr James McMahon, Infectious diseases physician & HIV researcher, The Alfred hospital & Monash Medical Centre, Melbourne, VIC, Australia</i>	Evolution of HIV-1 Drug Resistance Mutations in NSW Over 10 Years (447) <i>Angie Pinto</i>	Criminalisation of Sex work and HIV - Exploring their intersection <i>Cameron Cox, Chief Executive Officer, Sex Workers Outreach Project Inc (SWOP), NSW, Australia</i>	Estimated contribution of undiagnosed HIV infections among gay and bisexual men to new HIV infections in Australia <i>Richard Gray</i>
12.00pm – 12.20pm	Contrasting effects of IFNα on immune responses in HIV infection <i>Dr Sonia Fernandez, Research Associate, School of Pathology & Laboratory Medicine, Translational Immunology Unit, University of WA, Australia</i>	Panel Discussion <i>Professor Jennifer Hoy, Dr Julian Elliott, Dr Mark Boyd, Dr James McMahon, Dr Mark Bloch, and Neil McKellar-Stewart</i>	PLHIV in Sero-Discordant Relationships: Changes in Viral Load and Sexual Practices from 1997 to 2012 (499) <i>Jennifer Power</i>	Spitting and Mandatory BBV Testing – Dragging us Back to the 80s (837) <i>Michael Frommer and Linda Forbes</i>	HIV Oral Fluid Confirmatory Testing Algorithm, Assay Development, Validation and Epidemiological Applications (832) <i>Kim Wilson</i>
12.20pm – 12.35pm	The Impact of HIV and Hepatitis B Virus on Hepatic Stellate Cell Activation Using a Novel in Vitro System (625) <i>Kasha Singh</i>		Discussion	Criminalisation and Responsibilisation: A Case Study of Victorian Responses to Intentional HIV Transmission (550) <i>Larissa Sandy</i>	Discussion
12.30pm – 2.00pm	Lunch and Poster Viewing in Exhibition Hall 1				
12.30pm – 2.00pm	ASHM AGM M1&2, Mezzanine Level				
12.30pm – 2.00pm	AFAO Community and Advocacy Hub - Exhibition Hall <i>The ATRAS study and the treatment access gap: NAPWHA Call for a snap to action on sex work - better prevention, treatment & care for sex workers: Scarlet Alliance PrEP campaign launch: QuAC LGBTI mental health and suicide prevention: MindOUT Queensland</i>				
2.00pm – 3.30pm	Theme B - Issues in HIV Management Room: Great Hall 1, Door 6, Mezzanine Level Chairs: Heather McNamee and Trent Yarwood	Theme C and D- Drug and Alcohol Session Room: Great Hall 2, Door 8, Mezzanine Level Chairs: Karen Price and Jason Ferris	Theme D - Sex, Identity and Resistance Room: Great Hall 3, Door 4, Foyer Level Chair: Tony Maynard	ASHM International Session - Opportunities and challenges for HIV diagnostics, monitoring and management in the Asia & Pacific regions Room: Great Hall 4, Door 1, Foyer Level Chairs: Patricia Price and Michelle O'Connor	Aboriginal and Torres Strait Islander Symposium - sponsored by AbbVie Room: M1&2, Mezzanine Level Chairs: Andrew Jolivette
2.00pm – 2.15pm	Clinic Network Collaboration and Patient Tracing To Maximize Retention in HIV Care (355) <i>James McMahon</i>	Narcotics Are Cheaper Than Food in Pakistan: Our PWIDs Are Dying From AIDS (943) <i>Not presented</i>	Working from young people's 'local knowledge' – towards a new agenda for sexual health research (181) <i>Stephen Bell</i>	Challenges in HIV diagnostics monitoring in resource limited settings in Asia Pacific – setting the scene <i>Levinia Crooks</i>	The Human T Lymphotropic Virus type 1 subtype c: a major cause of morbidity and mortality for the Aboriginal people in central Australia <i>Dr Lloyd Einsiedel, Associate Director Research, Aboriginal Health, BakerIDI, Alice Springs Hospital, NT Australia</i>

THURSDAY 17 SEPTEMBER											
2.15pm – 2.30pm	Patient Retention in HIV Medical Care in a Primary Care Practice in Sydney, Australia (753) <i>Mark Bloch</i>	2.15pm – 2.30pm	Drug-related Hospital Admissions in HIV-infected and Uninfected Gay and Bisexual Men (691) <i>Cecilia Moore</i>	2.15pm – 2.30pm	PASH.tm: Gay, bisexual and queer transgender men in the HIV response (239) <i>Teddy Cook and Jeremy Wiggins</i>	2.05pm – 2.35pm	Challenges in HIV diagnostics experiences from: Papua New Guinea Samoa <i>Oscillah Kaminieel Sandra Semi</i>	2.20pm – 2.30pm	What's different about the novel Australian virus subtype; HTLV-1c <i>Professor Damian Purcell, Head, Molecular Virology Laboratory, Peter Doherty Institute for Infection and Immunity, University of Melbourne, VIC, Australia</i>		
2.30pm – 2.45pm	Factors associated with adherence to antiretroviral therapy in HIV-infected Australian adults: The PAART study (351) <i>Krista Siefried</i>	2.30pm – 2.45pm	The Highs and Lows of Methamphetamine use among Gay and Bisexual Men (515) <i>Mo Hammoud</i>	2.30pm – 2.45pm	The Social and Sexual Dynamic between Gay Men/Transgender People and Their Straight-Identifying Male Partners in Timor-Leste (448) <i>David Fowler</i>	2.35pm – 2.50pm	Experiences & opportunities in the use of dried blood spots in resource limited settings <i>Philip Cunningham</i>	2.30pm – 2.45pm	STI/HIV Concordance Testing: Findings from the Strive Study <i>Associate Professor James Ward, Head Aboriginal Health Infectious Diseases South Australian Health and Medical Research Institute, Adelaide, SA, Australia</i>		
2.45pm – 3.00pm	Effects of HIV Treatment Interruption in the Asia-Pacific Region – results from TAHOD (074) <i>Awachana Jiamsakul</i>	2.45pm – 3.00pm	Gay and Bisexual Men Alternate Ways of Obtaining Erectile Dysfunction Medication and their Reasons for Use (513) <i>Mo Hammoud</i>	2.45pm – 3.00pm	Shifting Identity among Young Same Sex Attracted Men and what it Means for HIV Risk: Building an Evidence Base for Effective HIV Prevention (833) <i>Sally Cameron</i>	2.50pm – 3.05pm	Development and Evaluation of a Simple, Filter Paper-Based Method of Plasma Separation and Storage to Enhance Accurate Virological Monitoring of HIV Patients in RLS (536) <i>Berhan Ayele Haile</i>	2.45pm – 3.00pm	Improving the Treatment Cascade for HIV Positive Aboriginal and Torres Strait Islander People at Cairns Sexual Health (452) <i>Joanne Leamy and Melanie Kielly-Terere</i>		
3.00pm – 3.15pm	Primary results of the Positive Outlook study: A randomised controlled trial of online self-management for gay men with HIV (321) <i>Tanya Millard</i>	3.00pm – 3.15pm	Crystal Methamphetamine Use Among Gay and Bisexual Men in Australia: Patterns of Use and Harm Reduction Responses (226) <i>Toby Lea</i>	3.00pm – 3.30pm	Discussion	3.05pm – 3.20pm	Cognitive evaluation needs in HIV patients; experience from Indonesia <i>Riwanti Estiasari</i>	3.00pm – 3.30pm	Gumbuya: Improving the treatment cascade for Aboriginal and Torres Strait Island people <i>Dr Darren Russell, Director, Sexual Health, Cairns Hospital; Chair, HIV Foundation Qld, Australia Professor Martyn French, Professor and Consultant, Clinical Immunology, University of Western Australia and Royal Perth Hospital, Perth, WA, Australia</i>		
3.15pm – 3.30pm	Self-Management for People Living with HIV: A Pilot of the Flinders Program™ in HIV Clinical Services (757) <i>Sarah Smith</i>	3.15pm – 3.30pm	Treatment outcomes from AC-ON's Substance Support Service: Working with HIV positive and at risk clients (240) <i>Toby Lea</i>			3.20pm – 3.30pm	Discussion <i>Patricia Price</i>				
3.30pm – 4.00pm	Afternoon Tea and Poster Viewing in Exhibition Hall 1										
3.30pm – 4.00pm	AFAO Community and Advocacy Hub - Exhibition Hall <i>Population mobility/CoPAHM: launch of Report Card</i>										

THURSDAY 17 SEPTEMBER											
4.00pm – 5.45pm	Theme A - Cure/Latency/CNS Room: Great Hall 1, Door 6, Mezzanine Level Chairs: Sarah Palmer and Lachlan Gray	4.00pm – 5.30pm	Theme B - Antiretroviral Therapy Room: Great Hall 2, Door 8, Mezzanine Level Chairs: James McMahon and David Baker	4.00pm – 5.30pm	Theme C - Evaluating Rapid HIV Testing Room: Great Hall 3, Door 4, Foyer Level Chairs: Levinia Crooks and Joe Debbatista	4.00pm – 5.30pm	Theme D- Bingo: The use of targets in HIV policy Room: Great Hall 4, Door 1, Foyer Level Chairs: Heather Worth and Larissa Sandy				
4.00pm – 4.20pm	HIV cure research: Current strategies and challenges <i>Professor Sharon Lewin, Director, Doherty Institute for Infection and Immunity, University of Melbourne, VIC, Australia</i>	4.00pm – 4.15pm	HIV treatment revision: As simple as old versus new? <i>Dr David Nolan, Consultant Physician, Department of Immunology, Royal Perth Hospital, Perth, WA, Australia</i>	4.00pm – 4.15pm	Who's Coming and Who's Coming Back? Characteristics of Rapid Testers and Return Testers at the Pronto! Community-Based HIV Testing Service (806) <i>Kathleen Elizabeth Ryan</i>	4.00pm – 4.05pm	MSM community perspectives on getting to 90/90/90 <i>Midnight Poonkasetwattana, Executive Director, APCOM (Asia Pacific Coalition on Male Sexual Health), Bangkok, Thailand</i>				
4.20pm – 4.40pm	Measuring the HIV reservoirs: New and improved methods <i>Associate Professor Sarah Palmer, Deputy Director, Centre for Virus Research, Westmead Millennium Institute and University of Sydney, NSW, Australia</i>	4.15pm – 4.30pm	Switching from a Tenofovir Disoproxil Fumarate (TDF)-Based Regimen to a Tenofovir Alafenamide (TAF)-Based Regimen: Data in Virologically Suppressed Adults Through 48 Weeks of Treatment (432) <i>Don Smith</i>	4.15pm – 4.30pm	What is The Cost Of Performing Parallel Conventional HIV Serology With Rapid HIV Testing When Delivering Sexual Health Screening For Gay And Bisexual Men? (820) <i>Damian Conway</i>	4.05pm – 4.20pm	Panel Member Perspectives <i>Professor Charles Gilks, David Fowler, Scientia Professor Peter Aggleton</i>				
4.40pm – 5.00pm	HIV Infection of the CNS: Implications for Cure <i>Dr Lachlan Gray, Senior Research Officer, The Burnet Institute, Melbourne, VIC, Australia</i>	4.30pm – 4.45pm	Consistency of Dolutegravir Treatment Difference in HIV+ Treatment Naives at Week 96 (729) <i>Mark Bloch</i>	4.30pm – 4.45pm	Missed Opportunities for STI Testing: A Mixed Methods Study of the Impact of a Stand-Alone HIV Testing Service (808) <i>Kathleen Elizabeth Ryan</i>	4.20pm – 5.30pm	Panel Discussion <i>Professor Charles Gilks, David Fowler, Scientia Professor Peter Aggleton, Midnight Poonkasetwattana, Professor Heather Worth and Dr Larissa Sandy</i>				
5.00pm – 5.15pm	PD-1 Identifies Latently HIV-infected Non-proliferating and Proliferating CD4+ T-cells (345) <i>Renee van der Sluis</i>	4.45pm – 5.00pm	Tenofovir Alafenamide Vs Tenofovir Disoproxil Fumarate, Each Co-Formulated with Elvitegravir, Cobicistat and Emtricitabine, for Initial Treatment of HIV-1 Infection: Two Randomised, Double-Blind, Phase 3, Non-Inferiority Trials (246) <i>Mark Bloch</i>	4.45pm – 5.00pm	HIV Testing Self-Efficacy is Associated with Higher HIV Testing Frequency and Perceived Likelihood to Self-Test Among Gay and Bisexual Men? (720) <i>Muhammad Shahid Jamil</i>						
5.15pm – 5.30pm	Antibody-Dependent Cellular Cytotoxicity against Cells Latently Infected with HIV (456) <i>Wen Shi Lee</i>	5.00pm – 5.15pm	Mortality among HIV Patients on Antiretroviral (ARV) Treatment in Bali, Indonesia 2006-2014: Incidence and Predictors (912) <i>Sri Utami</i>	5.00pm – 5.15pm	Sexual Risk Behaviour Predicts More Frequent use of HIV Self-Testing: Early Findings from the FORTH Trial (722) <i>Rebecca Guy</i>						
5.30pm – 5.45pm	Discovery of Novel Latency Reversing Agents (LRAS) that Specifically Reactivate HIV-1 (530) <i>Damian Purcell</i>	5.15pm – 5.30pm	Discussion	5.15pm – 5.30pm	Discussion						
5.30pm – 6.30pm	Networking Reception										
6.15pm – 8.30pm	Gilead Symposium - #Wheretonex Meeting Room 1 & 2, Mezzanine Level										
6.15pm – 6.45pm	Food and beverage service										
6.45pm – 8.30pm	Professor Andrew Carr - focussing on single tablet regimens and ask the question: is this regimen for a lifetime? Professor Darren Russell - focussing on using existing treatments as prevention; how can we make the playground safer? Rubern Meerman - highlighting how innovative thinking, and application of scientific investigation might deliver outcomes beyond today's expectations										

FRIDAY 18 SEPTEMBER

6.30am	Registration opens			
7.00am – 8.20am	Case Presentation Breakfast Room: Great Hall 1, Door 6, Mezzanine Level Chairs: David Nolan and Theo Van Lieshout			
7.00am- 7.20am	Breakfast To be served outside the room and not to be taken inside the auditorium			
7.20am – 7.40am	Case study: A Genital Bump (019) <i>Bianca F. Parsons</i>			
7.40am - 8.00am	Multiple Intracerebral Lesions in a Young Male (784) <i>Basavaprabhu Achappa</i>			
8.00am - 8.20am	Sarcoidosis in Human Immunodeficiency Virus (HIV): The Paradox of Autoimmunity in Immunodeficiency (408) <i>Ramona Muttucumar</i>			
8.30am – 10.00am	HIV&AIDS Conference Plenary 3 Room: Great Hall 4, Door 1, Foyer Level Chairs: Edwina Wright and Damian Purcell			
8.30am – 9.00am	Why should we switch for toxicity? (Theme B) <i>Dr Patrick (Paddy) Mallon, Associate Dean for Research and Innovation, School of Medicine and Medical Science, University College Dublin (UCD), Ireland</i>			
9.00am – 9.30am	HIV Gene Therapy (Theme A) <i>Geoff Symonds, PhD Head of Scientific Affairs and Collaborators, Calimmune Inc, Sydney, NSW, Australia</i>			
9.30am – 10.00am	Indian Blood: Two-Spirit Return, Mixed-Race Identity, and Critical Interventions in HIV (Aboriginal & Torres Strait Islander Health Theme) <i>Andrew Jolivet, Chair, American Indian Studies Department, San Francisco State University, USA</i>			
10.00am- 10.30am	Morning Tea and Poster Viewing in Exhibition Hall 1			
10.00am- 10.30am	AFAO Community and Advocacy Hub - Exhibition Hall <i>Testing advocacy update: ACON</i>			
10.30am – 12.00pm	Theme A - Fitness /Tat/ Gene therapy Room: Great Hall 1, Door 6, Mezzanine Level Chairs: Sarah Palmer and David Harrich	10.30am – 12.00pm Theme B - Co-morbidities Room: Great Hall 2, Door 8, Mezzanine Level Chairs: Fiona Bisshop and Mark Bloch	10.30am – 12.00pm Theme C - Gay Men, Sex and HIV Risk Reduction Room: Great Hall 3, Door 4, Foyer Level Chairs: Jeffrey Klausner and Anthony Lyons	10.30am – 12.00pm Theme D - HIV and Migration Room: Great Hall 4, Door 1, Foyer Level Chair: Bridget Haire
10.30am – 10.50am	Impact of transmitted virus replicative fitness on HIV-1 disease progression <i>Dr Eric Hunter, Professor of Pathology & Laboratory Medicine, Emory University, Centre for AIDS Research, Atlanta, USA</i>	10.30am – 10.50am Practical Management and Screening of Bone Disease in HIV <i>Professor Jennifer Hoy, Director HIV Medicine, Alfred Hospital and Monash University, Melbourne, Victoria, Australia</i>	10.30am – 10.45am Negotiating Change in Relationship Agreements (471) <i>Steven Philpot</i>	10.30am - 10.45am Asylum seekers, immigration detention are HIV: What are the issues? <i>Dr Bridget Haire, Post-doctoral Research Fellow, Kirby Institute UNSW; President Australian Federation of AIDS Organisations (AFAO), NSW</i>
10.50am – 11.10am	Development of a New Quantitative Intracellular HIV-1 MRNA Assay (Spliced-Tat) for the Detection of Active Virus Production within HIV-1 Reservoirs (803) <i>Kazuo Suzuki</i>	10.50am – 11.05am Changes in Renal Laboratory Parameters and Bone Mineral Density in Treatment-Naive HIV-1-Infected Adolescents Initiating Therapy with INSTI-Based Single-Tablet Regimens Containing Tenofovir Alafenamide (TAF) or Tenofovir Disoproxil Fumarate (TDF) (695) <i>Wasana Prasitsuebsai</i>	10.45am – 11.00am Boyfriends and Fuckbuddies: Defining Partners (489) <i>Benjamin Bavinton</i>	10.45am – 11.15am ARV access for Medicare Ineligible and the ATRAS study <i>Dr Kathy Petoumenos, Senior Lecturer, Biostatistics and Databases Program, The Kirby Institute, Sydney, NSW, Australia</i> <i>Aaron Cogle, Executive Director, National Association of People with HIV Australia (NAPWA), Sydney, NSW, Australia</i>
11.10am – 11.20am	Nullbasic Inhibits HIV Replication Through A Latency-Like Suppression of HIV-1 Gene Expression in Jurkat Cells (555) <i>Hongping Jin</i>	11.05am – 11.20am HIV Positive Outpatients With Treated Hypertension: Failure To Achieve Blood Pressure Targets (642) <i>Shanti Narayanasamy</i>	11.00am – 11.15am Making Relationships Work: How Much is Age a Factor? (492) <i>Garrett Prestage</i>	

FRIDAY 18 SEPTEMBER

11.20am – 11.30am	The Interaction of eEf1A and HIV RT is Critical for HIV-1 Reverse Transcription and a Potential Anti-HIV Target (525) <i>Dongsheng Li</i>	11.20am – 11.35am Prevalence and Correlates of HIV-Associated Dementia in HIV Outpatients in Ho Chi Minh City, Vietnam (443) <i>Truc Thanh Thai</i>	11.15am – 11.30am The Emergence of Undetectable Viral Load as a HIV Risk Reduction Strategy by Australian Gay and Bisexual Men Who have Condomless Sex with Casual Partners (101) <i>Martin Holt</i>	11.15am – 11.30am Moving targets <i>Dr Christopher Lemoh, Physician, Monash Health, Melbourne, VIC, Australia</i>
11.30am – 11.40am	Binding of the Eukaryotic Translation Elongation Factor 1A with the 5'UTR of HIV-1 Genomic RNA is Important for Reverse Transcription (467) <i>Ting Wei</i>	11.35am – 11.50am Management guidelines for HIV-related Co-morbidities Result in Increased Screening but no Change in Primary Prevention Implementation (106) <i>Janine Trevillyan</i>	11.30am – 11.45am Agreements and Communication about Viral Load and Condomless Anal Intercourse within Homosexual Male Serodiscordant Couples: Implications for 'Treatment as Prevention' (416) <i>Benjamin Bavinton</i>	11.30am – 12.00pm Panel Discussion <i>Dr Bridget Haire, Aaron Cogle, Dr Christopher Lemoh, and Dr Kathy Petoumenos</i>
11.40am – 11.50am				
11.50am – 12.00pm	Discussion	11.50am – 12.00pm Australian HIV/Hepatitis C Co-Infected Patients Fall Behind HIV Mono-Infected Patients in move towards Early HIV Treatment Initiation <i>Clara Brown</i>	11.45am – 12.00pm Discussion	
12.00pm – 1.30pm	Lunch and Poster Viewing in Exhibition Hall 1			
12.00pm – 1.30pm	AFAO Community and Advocacy Hub - Exhibition Hall <i>Remembering, Recognising and Responding: 21 years of the Anwernekenhe National HIV Alliance</i> <i>2Spirits Program</i> <i>Partnerships with faith leaders to address HIV stigma in Australia: AFAO and CEH</i>			
12.30pm- 1.15pm	Oral Poster Session - Theme B. Facilitator: John McBride Poster No. 12- Impact of a Pharmacist Review during Annual Health Checks in HIV patients taking combination antiretroviral therapy - Ivette Aguirre Poster No. 17 - Safety of Tenofovir Alafenamide in Renal Impairment - Mark Bloch Poster No. 21 - Utilisation of Dried Blood Spots (DBS) for Assessing Efavirenz Pharmacokinetics in ENCORE1 - Dianne Carey Poster No. 24 - Is HIV associated cognitive impairment a concern for PLHIV? - Denise Cummins Poster No. 25 - PLHIV self assessment tool for recognising signs and symptoms of HIV cognitive impairment - Denise Cummins Poster No. 30 - Predictors of Increased Immunological Response Within 24 Months of Art Among Art Naive Patients in Yogyakarta, Indonesia - Hastuti Poster No. 32 - Use of Concomitant Medications in HIV-1 Infected Patients in a Large Community Practice in Sydney, Australia - Avindra Jayewardene Poster No. 54 - Predictors of Mortality among HIV Patients on Antiretroviral Treatment in Dr. Sardjito Hospital Yogyakarta - Yurniati			
12.30pm- 1.00pm	Oral Poster Session - Theme D. Facilitator: Duc Nguyen Poster No. 123 - Creating opportunities for change in HIV policy – a case study of election advocacy in NSW - Dean Price Poster No. 126 - How do we get the Research Policy-Makers need in HIV and STI'S? - Heather-Marie Schmidt			

FRIDAY 18 SEPTEMBER					
1.30pm – 3.00pm	Theme A - Infection of CCR5+ CD4 T cells and its consequences Room: Great Hall 1, Door 6, Mezzanine Level Chairs: John Zaunders and Martyn French	1.30pm – 3.00pm	Theme B - ARV Guidelines Session 2: PrEP Room: Great Hall 2, Door 8, Mezzanine Level Chairs: Julian Elliott	1.30pm – 3.00pm	Theme C - Culture, Sex and Technology Room: Great Hall 3, Door 4, Foyer Level Chairs: Martin Holt and Graham Brown
1.30pm – 2.00pm	Diversity of CCR5+ CD4+ T cells <i>Dr John Zaunders, Senior Scientist, Centre for Applied Medical Research, St Vincent's Hospital; Conjoint Senior Lecturer, Immunovirology and Pathogenesis Program, Kirby Institute, UNSW, Sydney, NSW, Australia</i>	1.30pm – 1.50pm	PrEP Update <i>Professor Robert Grant, Professor of Medicine, University of California, San Francisco, USA</i>	1.30pm – 1.45pm	Male Sex Workers and Relationships with their Clients in Australia (498) <i>Garrett Prestage</i>
		1.50pm – 2.10pm	The Australian National PrEP guidelines and potential impact of PrEP on HIV prevention in Australia <i>Dr Iryna Zablotska, HIV Epidemiology and Prevention Program, The Kirby Institute, UNSW Australia</i>	1.45pm – 2.00pm	Is Acculturation a Major Factor for HIV Related Risk Taking Behaviours Among South Asian Immigrant Men-Who-Have-Sex-With-Men in Australia? (196) <i>Ahm Haque</i>
2.00pm – 2.30pm	Molecular gymnastics: HIV-1 R5 resistance to CCR5 antagonists and impact on viral phenotype <i>Dr Michael Roche, Postdoctoral Fellow, Doherty Institute for Infection and Immunity, University of Melbourne, VIC, Australia</i>	2.10pm – 2.20pm	PrEP in primary care <i>Dr Vincent Cornelisse, Registrar in Sexual Health Medicine (RACP), General Practitioner, Prahran Market Clinic, Melbourne, VIC, Australia</i>	2.00pm – 2.15pm	The Use of Mobile Phone Apps to Meet Partners by Gay Men in Australia is Not Associated with Increased Risk-Taking: Findings from the Gay Community Periodic Surveys, 2014 (816) <i>Peter Hull</i>
		2.20pm – 2.30pm	PrEP at the coalface <i>Dr Mark Bloch, Director, Holdsworth House Medical Practice, Sydney, NSW, Australia</i>	2.15pm – 2.30pm	Public Sexual Health Clinics Increase Access, HIV Testing and Re-Testing Among Higher Risk Gay and Bisexual Men (824) <i>Muhammad Jamil</i>
2.30pm – 2.45pm	SIV entry into T follicular helper (Tfh) cells may be associated with CCR5+ pre-Tfh cells in lymph node (LN) (180) <i>Yin Xu</i>	2.30pm – 2.40pm	PrEP availability and access options in Australia <i>Associate Professor Edwina Wright, Department of Infectious Diseases Alfred Health & Monash University, Burnet Institute, Melbourne, VIC, Australia</i>	2.30pm – 2.45pm	'It's Like Cooking an Egg': Exploring Gay and Bisexual Men's Responses to HIV Self-Testing (650) <i>Denton Callander</i>
2.45pm – 3.00pm	Pharmacological Ablation of Cellular Inhibitors of Apoptosis (Ciaps) Rapidly Sensitises HIV-Infected CD4+ T Cells to Death, Impeding Viral Spread and Immune Attrition in Humanized Mice (444) <i>Cody Allison</i>	2.40pm – 3.00pm	Panel Discussion: PrEP use in Australia, now and into the future <i>Professor Robert Grant, Dr Iryna Zablotska, Dr Vincent Cornelisse, Dr Mark Bloch, Associate Professor Edwina Wright, Dr Julian Elliott, James Gray</i>	2.45pm – 3.00pm	Discussion
3.00pm – 3.30pm	Afternoon Tea and Poster Viewing in Exhibition Hall 1				
3.00pm – 3.30pm	AFAO Community and Advocacy Hub - Exhibition Hall <i>HIV Futures 8: Australian Research Centre in Sex, Health and Society</i>				

FRIDAY 18 SEPTEMBER					
3.30pm – 5.00pm	Theme A - ACH ² Room: Great Hall 1, Door 6, Mezzanine Level Chairs: Gilda Tachedjian and Tony Cunningham	3.30pm – 5.00pm	Theme B - HIV Populations and Models of Care Room: Great Hall 2, Door 8, Mezzanine Level Chairs: Peter Watts and Diane Rowling	3.30pm – 5.00pm	ASHM International Session - Understanding and expanding the role of professional societies in capacity development in Asia & Pacific Regions Room: Great Hall 3, Door 4, Foyer Level Chairs: Mark Boyd and Scott McGill
3.30pm – 3.50pm	Novel latency reversing agents that specifically activate HIV gene expression <i>Professor Damian Purcell, Head, Molecular Virology Laboratory, Peter Doherty Institute for Infection and Immunity, University of Melbourne, VIC, Australia</i>	3.30pm – 3.45pm	Adolescents - whatever, or what-about-me? <i>Associate Professor Penelope Bryant, Infectious Diseases Physician, Department of General Medicine, The Royal Children's Hospital, VIC, Australia</i>	3.30pm – 3.45pm	Strengthening and expanding a network of professional organisations in Asia & Pacific – why now and why is this so critical <i>Levinia Crooks</i>
		3.45pm – 4.00pm	The lived experience of long-term survivors ageing with HIV in regional Queensland: Preliminary findings of a longitudinal Study (211) <i>Bernard Gardiner</i>	3.45pm – 4.00pm	The role of a professional society – perspectives from the Pacific <i>Arvin Chaudhary</i>
3.50pm – 4.10pm	Molecular interventions to HIV transmission at the sexual mucosae <i>Dr Andrew Harman, Senior Research Fellow, Medicine, Westmead Clinical School, Westmead Millennium Institute for Medical Research, NSW, Australia</i>	4.00pm – 4.15pm	Antiretroviral Treatment (ART) Outcomes for Pediatric HIV-Infected Patients in Vietnam (2006–2010) (461) <i>Nguyen Binh</i>	4.00pm – 4.15pm	Ongoing clinical mentoring – an essential part of capacity development and quality of care <i>Arun Menon</i>
4.10pm – 4.30pm	Inhibiting HIV-1 Reverse Transcription by Destabilizing the Reverse Transcription Complex (495) <i>David Harrich</i>	4.15pm – 4.30pm	Trends in CD4 cell count and HIV viral load suppression in Asian adolescents (688) <i>Azar Kariminia</i>	4.15pm – 4.30pm	Capacity development needs for HIV/SRH providers in the Pacific <i>Silina Motufaga</i>
4.30pm – 4.45pm	Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening <i>Associate Professor Gilda Tachedjian, Head, Retroviral Biology and Antivirals Laboratory, Burnet Institute, VIC, Australia</i>	4.30pm – 4.45pm	Anti-Retroviral Treatment: Changing Attitudes among PLHIV from 1997 To 2012(472) <i>Jennifer Power</i>	4.30pm – 4.45pm	Importance of measuring capacity in organisational development – designing a tool <i>David Fowler</i>
4.45pm – 5.00pm	Development of Nuclear Import Inhibitors as Anti-HIV Agents (533) <i>Kylie Wagstaff</i>	4.45pm – 5.00pm	Not so Hard to Swallow? Early Adherence to PrEP by the First 50 Participants in the VicPrEP Study (689) <i>Jennifer Audsley</i>	4.45pm – 5.00pm	Discussion and closing remarks <i>Mark Boyd & Scott McGill</i>
5.00pm – 5.15pm	Conference closing message in every session room				
5.30pm	Conference close				